Johnson & Johnson vaccine receives green light from European regulator
The EMA believes that the overall benefit-risk balance of using Johnson & Johnson's vaccine remains positive.
AP - David Zalubowski
Text by: RFI Follow
For the European Medicines Agency (EMA), the Johnson & Johnson vaccine against Covid-19, on which many countries rely to speed up immunization campaigns, can be used, due to a favorable benefit / risk ratio .
In a ruling on Tuesday, the European Medicines Agency ruled that blood clots that have occurred in a few vaccinated people should be listed as a "
" side effect of the Johnson & Johnson vaccine.
The EMA finds a possible link with very rare cases of unusual blood clots associated with low blood platelets
," said the European regulator, adding that this "
confirms that the overall benefit-risk balance remains positive
The CFO of Johnson & Johnson (J&J) had previously said the laboratory remained "
" about its vaccine and hoped to find "
" a solution with regulators on its use,
currently suspended in Europe and the United States
This decision was eagerly awaited by several European countries, including France, which rely on the J&J vaccine, having the advantage of requiring only one dose, to speed up their immunization campaign.
AstraZeneca and Janssen's anti-Covid vaccines are "
" to achieve the objectives of the vaccination campaign in France, the Ministry of Health said on Tuesday.
To read also: France: vaccination opens to all over 55 years
In the United States, health authorities recommended last Tuesday "
" in its use to investigate the appearance of serious cases of blood clots.
However, its use should be re-authorized, perhaps accompanied by "
" and a decision should be made public by Friday, White House medical adviser Anthony Fauci said on Sunday.
Receive all international news directly in your mailbox
Follow all the international news by downloading the RFI application
Health and medicine